Immuron launch PROIBS for IBS
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immuron Limited has announced the launch of PROIBS for treating Irritable Bowel Syndrome in Australia, with initial pharmacy orders already received. The product is designed to alleviate symptoms such as abdominal pain and bloating, and is positioned to be available online and in selected pharmacies. The Chief Commercial Officer emphasized the importance of this launch coinciding with the peak festive season when IBS symptoms are most prevalent.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Immuron
- Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
- Immuron Q1 FY26 YoY growth
- Immuron Submits IMM-529 IND to FDA
- Immuron Letter to Shareholders – Projects Update
- FY25 Results Presentation
Later from Immuron
- Clinical Trial Update
- Immuron Announces Clinical Trial Update
- IMM-529 IND approved by FDA
- Immuron New U.S. Department of Defense Award & Clinical Trial Update
- Uniformed Services University to Release Topline Data
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron